187 related articles for article (PubMed ID: 34120207)
1. LI-RADS treatment response assessment of combination locoregional therapy for HCC.
Gerena M; Molvar C; Masciocchi M; Nandwana S; Sabottke C; Spieler B; Sharma R; Tsai L; Kielar A
Abdom Radiol (NY); 2021 Aug; 46(8):3634-3647. PubMed ID: 34120207
[TBL] [Abstract][Full Text] [Related]
2. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
[TBL] [Abstract][Full Text] [Related]
3. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
[TBL] [Abstract][Full Text] [Related]
4. Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.
Patel R; Aslam A; Parikh ND; Mervak B; Mubarak E; Higgins L; Lala K; Conner JF; Khaykin V; Bashir M; Do RKG; Burke LMB; Smith EN; Kim CY; Shampain KL; Owen D; Mendiratta-Lala M
J Magn Reson Imaging; 2023 Jun; 57(6):1641-1654. PubMed ID: 36872608
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
6. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy.
Kampalath R; Tran-Harding K; Do RKG; Mendiratta-Lala M; Yaghmai V
Magn Reson Imaging Clin N Am; 2021 Aug; 29(3):389-403. PubMed ID: 34243925
[TBL] [Abstract][Full Text] [Related]
7. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence in assessment of hepatocellular carcinoma treatment response.
Spieler B; Sabottke C; Moawad AW; Gabr AM; Bashir MR; Do RKG; Yaghmai V; Rozenberg R; Gerena M; Yacoub J; Elsayes KM
Abdom Radiol (NY); 2021 Aug; 46(8):3660-3671. PubMed ID: 33786653
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
11. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
[TBL] [Abstract][Full Text] [Related]
12. LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.
Kim TH; Woo S; Joo I; Bashir MR; Park MS; Burke LMB; Mendiratta-Lala M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3717-3728. PubMed ID: 34027566
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
15. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.
Alnammi M; Wortman J; Therrien J; Afnan J
Abdom Radiol (NY); 2022 Jul; 47(7):2299-2313. PubMed ID: 35524803
[TBL] [Abstract][Full Text] [Related]
16. Imaging diagnosis of hepatocellular carcinoma: LI-RADS.
Cunha GM; Sirlin CB; Fowler KJ
Chin Clin Oncol; 2021 Feb; 10(1):3. PubMed ID: 32527115
[TBL] [Abstract][Full Text] [Related]
17. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
18. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
19. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
[TBL] [Abstract][Full Text] [Related]
20. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
